Dr. Galsky, Professor of Medicine, Director of Genitourinary Medical Oncology, Director of the Novel Therapeutics Unit, and Co-Director, Center of Excellence for Bladder Cancer, The Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai, tells us about the outcomes of the PROfound study whether medical oncologists should olaparib in the management of their metastatic castration-resistant prostate cancer (mCRPC) patients